NANTES, France & BASEL, Switzerland–Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, today announced a collaboration with TcLand Expression, a world-leading company in the field of gene expression biomarkers for autoimmune disorders and transplantation. As part of the collaboration, the Genedata Phylosopher® and Expressionist® biomarker discovery platforms will be integrated into TcLand Expression’s computational infrastructure. The integral press release is available by clicking here.

TcLand Expression is pioneering work in the field of personalized medicine for transplantation and autoimmune diseases. The company is developing gene expression signatures in collaboration with health care professionals and patients worldwide. The Genedata Expressionist® and Phylosopher® platforms will serve as a scalable core infrastructure supporting interdisciplinary biomarker identification, validation and mode-of-action studies. The platform will enable TcLand Expression’s researchers to take a cross-technology approach by using automated workflows and integrated analysis tools to streamline the research workflow, from experimental design through to final results.

About TcLand Expression

TcLand Expression is a recognized pioneer in the discovery and development of gene expression biomarkers for unmet medical needs in transplantation and auto-immune diseases. The company benefits from an exceptional scientific environment and is focusing on two major therapeutic areas with huge remaining unmet needs: transplantation and auto-immune diseases. http://www.tcland-expression.com.

About Genedata

Genedata develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata’s solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high throughput technologies. Solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston and San Francisco, USA, Konstanz and Munich, Germany and Tokyo, Japan. For more information, please visit www.genedata.com.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.